Cargando…

T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma

Immunotherapies relying on type 1 immunity have shown robust clinical responses in some cancers yet remain relatively ineffective in solid breast tumors. Polarization toward type 2 immunity and expansion of myeloid-derived suppressor cells (MDSC) confer resistance to therapy, though it remains uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasé, Viva J., Hayward, Reid, Haughian, James M., Pullen, Nicholas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498998/
https://www.ncbi.nlm.nih.gov/pubmed/36142210
http://dx.doi.org/10.3390/ijms231810299
_version_ 1784794899785187328
author Rasé, Viva J.
Hayward, Reid
Haughian, James M.
Pullen, Nicholas A.
author_facet Rasé, Viva J.
Hayward, Reid
Haughian, James M.
Pullen, Nicholas A.
author_sort Rasé, Viva J.
collection PubMed
description Immunotherapies relying on type 1 immunity have shown robust clinical responses in some cancers yet remain relatively ineffective in solid breast tumors. Polarization toward type 2 immunity and expansion of myeloid-derived suppressor cells (MDSC) confer resistance to therapy, though it remains unclear whether polarization toward type 3 immunity occurs or has a similar effect. Therefore, we investigated the involvement of type 3 T(h)17 and T(h)22 cells and their association with expanding MDSC populations in the 4T1 mouse mammary carcinoma model. T(h)17 and T(h)22 were detected in the earliest measurable mass at d 14 and remained present until the final sampling on d 28. In peripheral organs, T(h)17 populations were significantly higher than the non-tumor bearing control and peaked early at d 7, before a palpable tumor had formed. Peripheral T(h)22 proportions were also significantly increased, though at later times when tumors were established. To further address the mechanism underlying type 3 immune cell and MDSC recruitment, we used CRISPR-Cas9 to knock out 4T1 tumor production of interleukin-6 (4T1-IL-6-KO), which functions in myelopoiesis, MDSC recruitment, and T(h) maturation. While 4T1-IL-6-KO tumor growth was similar to the control, the reduced IL-6 significantly expanded the total CD4(+) T(h) population and T(h)17 in tumors, while T(h)22 and MDSC were reduced in all tissues; this suggests that clinical IL-6 depletion combined with immunotherapy could improve outcomes. In sum, 4T1 mammary carcinomas secrete IL-6 and other factors, to polarize and reshape T(h) populations and expand distinct T(h)17 and T(h)22 populations, which may facilitate tumor growth and confer immunotherapy resistance.
format Online
Article
Text
id pubmed-9498998
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94989982022-09-23 T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma Rasé, Viva J. Hayward, Reid Haughian, James M. Pullen, Nicholas A. Int J Mol Sci Article Immunotherapies relying on type 1 immunity have shown robust clinical responses in some cancers yet remain relatively ineffective in solid breast tumors. Polarization toward type 2 immunity and expansion of myeloid-derived suppressor cells (MDSC) confer resistance to therapy, though it remains unclear whether polarization toward type 3 immunity occurs or has a similar effect. Therefore, we investigated the involvement of type 3 T(h)17 and T(h)22 cells and their association with expanding MDSC populations in the 4T1 mouse mammary carcinoma model. T(h)17 and T(h)22 were detected in the earliest measurable mass at d 14 and remained present until the final sampling on d 28. In peripheral organs, T(h)17 populations were significantly higher than the non-tumor bearing control and peaked early at d 7, before a palpable tumor had formed. Peripheral T(h)22 proportions were also significantly increased, though at later times when tumors were established. To further address the mechanism underlying type 3 immune cell and MDSC recruitment, we used CRISPR-Cas9 to knock out 4T1 tumor production of interleukin-6 (4T1-IL-6-KO), which functions in myelopoiesis, MDSC recruitment, and T(h) maturation. While 4T1-IL-6-KO tumor growth was similar to the control, the reduced IL-6 significantly expanded the total CD4(+) T(h) population and T(h)17 in tumors, while T(h)22 and MDSC were reduced in all tissues; this suggests that clinical IL-6 depletion combined with immunotherapy could improve outcomes. In sum, 4T1 mammary carcinomas secrete IL-6 and other factors, to polarize and reshape T(h) populations and expand distinct T(h)17 and T(h)22 populations, which may facilitate tumor growth and confer immunotherapy resistance. MDPI 2022-09-07 /pmc/articles/PMC9498998/ /pubmed/36142210 http://dx.doi.org/10.3390/ijms231810299 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rasé, Viva J.
Hayward, Reid
Haughian, James M.
Pullen, Nicholas A.
T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma
title T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma
title_full T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma
title_fullStr T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma
title_full_unstemmed T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma
title_short T(h)17, T(h)22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma
title_sort t(h)17, t(h)22, and myeloid-derived suppressor cell population dynamics and response to il-6 in 4t1 mammary carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498998/
https://www.ncbi.nlm.nih.gov/pubmed/36142210
http://dx.doi.org/10.3390/ijms231810299
work_keys_str_mv AT rasevivaj th17th22andmyeloidderivedsuppressorcellpopulationdynamicsandresponsetoil6in4t1mammarycarcinoma
AT haywardreid th17th22andmyeloidderivedsuppressorcellpopulationdynamicsandresponsetoil6in4t1mammarycarcinoma
AT haughianjamesm th17th22andmyeloidderivedsuppressorcellpopulationdynamicsandresponsetoil6in4t1mammarycarcinoma
AT pullennicholasa th17th22andmyeloidderivedsuppressorcellpopulationdynamicsandresponsetoil6in4t1mammarycarcinoma